Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.46 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 2/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30100510 | 0.97 | HPGD (0.44) | HPGDSMN1; SMN2LMNANPSR1EPHX1 | |
| SCHEMBL1236881 | 0.90 | HPGD (0.56) | HPGDSMN1; SMN2LMNANPSR1EPHX1 | |
| SCHEMBL1237684 | 0.90 | HPGD (0.56) | HPGDSMN1; SMN2LMNANPSR1EPHX1 | |
| SCHEMBL1237682 | 0.90 | HPGD (0.56) | HPGDSMN1; SMN2LMNANPSR1EPHX1 | |
| SCHEMBL1236882 | 0.90 | HPGD (0.56) | HPGDSMN1; SMN2LMNANPSR1EPHX1 | |
| SCHEMBL30100493 | 0.88 | CNR1 (0.48) | — | |
| SCHEMBL31131450 | 0.86 | SPHK1 (0.41) | HPGDSMN1; SMN2LMNANPSR1EPHX1 | |
| SCHEMBL30100540 | 0.85 | ADRA1A (0.47) | HPGDSMN1; SMN2LMNANPSR1CYP3A4 | |
| SCHEMBL31131448 | 0.83 | SPHK1 (0.38) | HPGDSMN1; SMN2LMNANPSR1EPHX1 | |
| SCHEMBL5408092 | 0.81 | EPHX2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605464-B2 | Cyclohexane lipidoids for nucleic acid transfection and use thereof | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2026-04-21 | — | — | US | disclosed |
| US-20240335559-A1 | CYCLOHEXANE LIPIDOIDS FOR NUCLEIC ACID TRANSFECTION AND USE THEREOF | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2024-10-10 | — | — | US | disclosed |
| EP-4373804-A1 | CYCLOHEXANE LIPIDOIDS FOR NUCLEIC ACID TRANSFECTION AND USE THEREOF | Ustav Organicke Chemie a Biochemie AV CR v.v.i. (CZ) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023001323-A1 | CYCLOHEXANE LIPIDOIDS FOR NUCLEIC ACID TRANSFECTION AND USE THEREOF | Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335559-A1 | CYCLOHEXANE LIPIDOIDS FOR NUCLEIC ACID TRANSFECTION AND USE THEREOF | SGMS2, NR1H3, SGMS1 | HPGD 2185/4885SMN1; SMN2 3086/4885LMNA 185/4885 |
| US-12605464-B2 | Cyclohexane lipidoids for nucleic acid transfection and use thereof | NR1H2, NPC1, NR1H3 | HPGD 2635/4885SMN1; SMN2 2548/4885LMNA 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.